Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?
Johnson & Johnson is positioned to achieve double-digit sales growth by 2030 following its consumer health spinoff. Despite facing a major patent cliff with Stelara losing exclusivity in 2025, the company's new drug launches (Icotyde, Inlexzo, Lazcluze, Imaavy) with peak sales potential exceeding $5 billion each, combined with its robotic surgery device Ottava and strong dividend history as a Dividend King, make it an attractive investment for long-term income seekers.
